(Q37765836)

English

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action

scientific article published on 16 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Matthew B Carroll

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Michael A Forgione

2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

publication date

16 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Clinical Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1021-1029

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B: the virus and disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of-238G/A and -857C/T polymorphisms of tumor necrosis factor-alpha gene promoter region with outcomes of hepatitis B virus infection.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Occult hepatitis B and infliximab-induced HBV reactivation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohnʼs disease patient

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine gene polymorphisms in patients infected with hepatitis B virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How to modulate inflammatory cytokines in liver diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic viral hepatitis and the human genome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the management of inflammatory bowel disease in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differentiating the new rheumatoid arthritis biologic therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular virology of hepatitis B virus for clinicians

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Problems encountered during anti-tumour necrosis factor therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrahepatic T cells in hepatitis B: viral control versus liver cell injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New drugs for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B Virus Infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of polymorphism of tumor necrosis factor-alpha gene promoter region with outcome of hepatitis B virus infection.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serious infections associated with anticytokine therapies in the rheumatic diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20556450

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10067-010-1523-2

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37765836&oldid=1727209338"